logo
  

Impax Laboratories Inc. (IPXL) Is Rising After FDA Approval

Impax Laboratories Inc. (IPXL) announced after the bell Monday that it has received approval from the FDA for a generic version of Renvela tablets, 800 mg. The stock is now up 1.05 on 34K shares.

Impax Laboratories gapped down slightly Monday and fell during the first hour of trade, before settling into a range. Shares finished with a loss of 0.90 at $20.35.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

Inflation data from the U.S. garnered maximum attention this week on the economics front, along with the interest rate decision by the European Central Bank. Read our stories to find out how these two key events are set to influence monetary policy in the months ahead. Other main news from the U.S. were the release of the minutes of the latest Fed policy session and the jobless claims data. Elsewhere, the interest rate decision by the Bank of Canada was also in focus.

View More Videos
Follow RTT